3e8 is an AI-native market research firm that combines deep life sciences expertise with agentic AI workflows to deliver insights that arrive fast, uncover the “why”, and are statistically sound.
The Challenge
Today, generating those insights is:
Slow
Scoping, designing, and fielding a typical MR study takes weeks.
Expensive
A typical study costs $100k–$300k.
Full of trade-offs
Forces you to choose between quantitative surveys for scale or qualitative for depth.
3e8 delivers insights that combine the depth of a qual with the rigor of a quant, and delivers them in days, not weeks, at a fraction of the cost.
How We Do It
Agentic workflows compress the logistics that used to take weeks. A pharma-grade voice moderator does the interviewing itself: adaptive, probing, and built around the same compliance discipline every pharma interview requires.
Turns your business question into a discussion guide, guardrails, and screener, ready for your review before anything goes live.
Researches your therapeutic area and product from accredited sources before the first interview, so the moderator already knows the landscape.
Runs the live voice interview itself: adaptive, probing, one question at a time, never a script read aloud.
Invites the right respondents to each study and follows up on its own, so fielding doesn't wait on manual outreach.
Turns raw interview transcripts into structured, quotable findings: the connective layer between what respondents said and what you need to decide.
Packages structured findings into the exact reporting format your team uses: sponsor-ready, without a week of deck-building.
A growing bench of agents running behind the scenes: payments, scheduling, and the logistics that used to slow research down.
A real, working team of specialized agents, not one model doing everything at once, compresses research design, recruiting, and synthesis down to days. Swipe through them →
How are you sequencing therapy for HR-low mBC patients today?
Pretty much the same as HR-positive, honestly.
What's driving that, given the biology's different?
Understands your therapy area, probes like a trained moderator, and follows the same consent discipline every pharma interview requires.
Solutions
Removing the logistics that constrained research for decades doesn’t just make studies faster. It makes new kinds of studies possible.
Stop choosing between the “why” and the “how many.” Our AI-moderated interviews blend qual probing and quant tracking into a single continuous conversation, capturing structured metrics and deep reasoning simultaneously, far more efficiently than a human moderator juggling both could.
Don’t launch a full-scale study for a single urgent business question. Once the logistics that made research slow and expensive are gone, the atomic unit shrinks from the study to the question itself: a grounded, real-time answer to whatever came up this week.
Move past static snapshots that go stale before the deck is even built. Keep a continuous pulse on the landscape with brief, recurring conversations (a few minutes every few days or weeks), tracking evolving perceptions and how a patient’s experience changes over time.
How We Partner
3e8 operates as a full-service market research partner, matching the exact engagement model of the consultants and research firms you already use.
No software to license, no platforms to learn, and no internal training required.
You bring us your strategic objectives. We design, recruit, field, and synthesize the research, keeping you informed at every step of our familiar, full-service workflow.
You receive polished, executive-ready deliverables in the exact formats you already use, with unmatched depth and none of the waiting.
We don’t change how you work. We just get you more out of every study.
Enterprise Security & Compliance
Biopharma market research demands rigorous data protection and regulatory discipline. Here’s what that actually means in our workflows today.
Why 3e8
Real commercial decisions require real-time feedback from physicians, patients, and payers, and not a deck stitched together weeks after the moment has passed. But traditional insights are often too slow and costly to get when you actually need them.
We’ve lived this problem ourselves. We have advised global biopharma executives, driven commercial strategy, and executed primary research that have fueled breakthrough therapies. 3e8 is the platform we always wished existed: uncompromised research rigor, delivered at the speed your decisions demand.
Ayush Mundhra
Founder & CEO, 3e8